The PVT1 locus is identified as a cluster of T(2;8) and T(8;22) ''variant'' MYC-activating chromosomal translocation breakpoints extending 400 kb downstream of MYC in a subset (
Introduction
For years, noncoding RNAs have represented an exception to the ''Central Dogma'' theory that RNA predominately encodes protein. Recently, a new series of noncoding RNAs have been discovered in a broad range of species, termed primary microRNAs (miRNA) that are processed into mature miRNAs of f21 to 22 nucleotides (nt) via an intermediate precursor miRNA (1) . Analysis of the distribution of miRNA genes in the human genome has suggested that many are found within genomically unstable regions. This finding has strengthened the argument that deregulated expression of miRNAs and/or their targets could be critical components in many disease processes, including cancer (2) . For example, a cluster of miRNAs resides on human chromosome 13q14, a frequently deleted chromosomal region in cancer (3) . The absence of involvement of any protein-encoding gene in this region coupled with the location of hsa-miR-15 and hsa-miR-16 within a 30-kb -deleted segment in chronic lymphocytic leukemia has suggested that, at least in this context, these miRNAs can function as tumor suppressors (4) . Other miRNAs that have been implicated in cancer include hsa-let-7, hsamir-155, and a cluster of miRNAs found within chromosome 13q31 that are frequently amplified in tumors from patients with various forms of lymphoma (5) (6) (7) (8) (9) .
An early example of a connection between cancer and chromosomal breakpoints are translocations associated with human chromosome 8q24 containing the gene encoding the proto-oncogene transcription factor MYC (Supplementary Fig. S1A ; ref. 10 ). In 80% of Burkitt's lymphoma (BL), a T(8;14) chromosomal translocation juxtaposes MYC to the IGH locus. Variant translocations [T(2;8) or T (8;22) ] are found in the remaining 20% of BLs, with breakpoints extending 400 kb downstream of MYC in a region referred to as PVT1. Because similar clusters of PVT1-associated chromosomal breakpoints or retroviral integration sites are found in mouse plasmacytomas (PCT) and rat immunocytomas, it has been suggested that altered expression of MYC is the target of this genomic instability (11) . For example, PVT1-involved translocations are often accompanied by a change in the initiation of MYC transcription from the normal P2 promoter to the stronger P1 promoter, which may lead to an overall increase in MYC expression (reviewed in ref. 10 ). However, evidence that additional factors are involved in MYC deregulation also exists, including the observation that MYC transcription levels vary immensely from one tumor to another, independent of breakpoint location (12) .
A plausible explanation for the interaction between MYC and PVT1 came with the discovery of PVT1-associated transcripts (13, 14) that initiate f40 to 60 kb downstream of MYC in the same transcriptional orientation. Despite the presence of alternatively spliced transcripts, variant chromosomal translocations [T (8;22) or T(2;8)] that juxtapose IG E or n light chain genes with PVT1 result in chimeric transcripts of 0.9 to 1.2 kb, which contain PVT1 exons 1a or 1b spliced directly to the constant region of IG E or n (Supplementary Fig. S1A ; refs. 15, 16) . Although these fusion transcripts are relatively abundant (as a consequence of the proximity to the IG enhancer), no protein product(s) have been found and therefore no biological role has been identified. In a study of multiple myeloma, 16% (7 of 42) of patients had rearrangements of the PVT1 region (independent of IG translocation) and this correlated with refractoriness to therapy (17) . In variant translocations of mouse PCTs, similar small chimeric transcripts are formed, which contain exon 1a fused directly to the IG light chain constant region. However, as seen with human PVT1, no protein product has been identified in mouse for either the fusion products or the normal PVT1 transcript. Although both human and mouse PVT1 are transcribed in the same direction as MYC, and in virtually all tissues, differences in the location (with reference to MYC) and the number of exons suggest that these transcriptional units may not be the same.
Genomic alterations of the chromosome 8q24 region have also been implicated in the development of solid tumors. Coamplification of human MYC and PVT1 seem to correlate with rapidly growing and progressive breast cancer and, as a prognostic factor, this amplicon has been associated with poor clinical survival in postmenopausal or HER2-positive breast cancer patients (18) . In breast cancer cell lines with MYC/PVT1 amplification, usually the entire MYC and PVT1 regions are coamplified, although microdeletions in the region of PVT1 Supplementary Fig. S1B ). 4 Nevertheless, the absence of uniformly deregulated MYC expression in many different types of epithelial and hematopoietic cancers (ovarian, colorectal, lung, head and neck, leukemia, and lymphoma) exhibiting coamplified MYC/PVT1 suggests a complex role for this region in tumorigenesis (20) (21) (22) (23) (24) (25) (26) .
MicroRNAs exert their effect on gene expression through a posttranscriptional gene silencing mechanism termed RNA interference where gene expression is down-regulated through either cleavage of the target transcript or, more typically, through suppression of protein translation. The %22-nt mature miRNAs mediate their effect on gene expression through the formation of ribonucleotide-protein complexes that use the miRNA as a guide for the alignment of the complex with a target transcript (27) . The sequence alignment between a miRNA and a mRNA transcript is a critical feature of this interaction. To date, little is understood about this alignment and its functional consequence, but minimal requirements seem to include an exact sequence alignment of %7 nt (at the 5 ¶ end of the mature miRNA) known as the seed sequence, and a variable number of matches and mismatches between the sequence target region and the miRNA for the remaining %15 nt. An important consequence of this imperfect sequence alignment is that each miRNA has the potential to interact with many target transcripts. Thus, a single miRNA could influence the expression of multiple critical genes in a transformation pathway, for example, by directly or indirectly affecting MYC expression. In this study, we have tested our hypothesis that the PVT1 region harbors previously unidentified miRNAs based on the following observations, (a) no PVT1 protein product has been found that might interact with MYC, (b) the observed differences in location of the mouse and human PVT1 transcriptional units lessen the importance of a conserved PVT1 transcript, and (c) clusters of miRNAs are frequently associated with regions of genomic instability (2, 28) .
Results

In silico Identification of PVT-Associated miRNAs
One explanation for the role of the PVT1 region in human vBL and mouse PCTs as well as epithelial cancers is the possibility that the PVT1 noncoding RNA may simply be a by-product of a transcriptionally active region harboring other transcriptional units, including miRNAs. In addition to our own cloning studies (Supplementary Fig. S1A ; refs 14, 24), a survey of human and mouse PVT1-associated sequences 5 shows extensive alternative splicing of transcripts from this region. To test the hypothesis that PVT1 contains heretofore uncharacterized miRNAs, we analyzed the 400-kb genomic sequence 3 ¶ of MYC, which includes the entire human PVT1 locus (University of California Santa Cruz, hg17, chr8: 128,830,208-129,253,652) and in multiple species by computational procedures, similar to previously described approaches (29) (30) (31) (32) . Principally, sequence conservation (primarily putative seed sequences) and secondary hairpin-facilitating structural properties were used as the main criteria for the selection of putative miRNA precursor structures. Conserved segments of 60 bp or more from the PVT1 region were extracted from the University of California Santa Cruz PhastCons annotation 6 based on the multiple alignments of six species (human, chimpanzee, dog, mouse, rat, and chicken). Any PhastCons elements separated by the gap of <20 bp were merged into one segment for structural analysis. A sliding window of 80 bp with an increment of 10 bp was scanned along the conserved segments. The sequence windows were folded using the RNAfold program (33) and the stem-loop structures with a total length of >50 bp and with at least 65% of paired bases were selected. The remaining sequences were refolded and the structures with a folding free energy of over a maximum of À15 kcal/mol were selected for experimental validation. The calculation of the free energy of the predicted secondary precursor structures was coupled with the ratio of the paired bases to the total length of the sequence. This analysis predicted 13 potential mature miRNA sequences (Table 1 ; Supplementary Fig. S2 ).
Validation of PVT1 miRNAs by Northern Analysis
Northern blot hybridization was used to test for expression of each of the miRNAs identified by the bioinformatics process using size-selected RNA (less than %30 nt) from BL, breast, and colon cancer cell lines with radioactively labeled ribonucleotide probes corresponding to each of the computationally predicted mature miRNA sequences (Supplementary Methods). The expression of six mature miRNA sequences was confirmed (Fig. 1A) . For the remaining seven miRNAs that were apparently not expressed, probes were made in the antisense direction and rechecked by Northern blot analysis to eliminate strand bias. Only hsa-miR-2PVT1 was expressed in an antisense direction and at very low levels (detected only after 1 month of exposure; data not shown). Overall, 7 of the 13 computationally predicted mature miRNA sequences were validated experimentally. Some miRNAs were expressed abundantly (hsa-miR-1204, hsa-miR-1207-5p, and hsa-miR-1207-3p) with similar patterns of expression among the cell lines, whereas others seem to be expressed at lower levels (hsa-miR-1205 and hsa-miR-1208). We also observed some examples of increased or decreased expression on an individual basis within the cell lines used. For example, hsa-miR-1207-3p is expressed abundantly in the colon cancer cell line HCT-116. Conversely, hsa-miR-1206 seems to be expressed only at low levels in the MDA-MB-231 breast cancer cell line. To establish a basis for comparison, the level of expression of a known human miRNA, hsa-miR-155, was also included as part of the Northern blot analysis.
We compared the sequences of these new mature miRNAs with previously reported miRNA sequences (MiRBase, Release 9.0). 7 Examination of the seed sequences for the validated PVT1-associated miRNAs revealed only minimal overlap (F1) with seed sequences from already annotated miRNAs (Table 1) . However, the seed sequence for hsa-miR-1205 is identical to the seed sequence for hsa-miR-17-3p, which is expressed in HeLa cells (34) . A sequence within hsa-miR-2PVT1 is the same as the seed sequence of the miRNA mmu-miR-698, a recently cloned miRNA from mouse embryos (35) . The hsa-miR-1207-3p sequence is related to a group of mammalian miRNAs with overlapping seeds [rno-miR-337 (28), mmu-miR-763 (36), and hsa-miR-565 (37)]. The lengths of the predicted precursor sequences are between 58 and 72 nt for most of the miRNAs. However, two miRNAs hsa-miR-1207-5p and hsamiR-1207-3p, which we originally considered to be independent overlapping precursors, may reside on complementary strands of a single, longer (87 nt) hairpin structure ( Table 1) . As mentioned above, both these miRNAs are expressed similarly across the cell lines when examined by Northern blot analysis (Fig. 1A) , suggesting a common promoter and transcriptional regulatory unit. Although such a precursor structure is relatively rare, previous reports have identified other examples of complementary overlapping miRNAs (e.g., let-7d and let-7d*; ref. 38) . How these miRNA species are processed and used is probably complex and will require further investigation. , and MYC in the human BL lines; Namalwa, CA46, and the vBL line PA682 compared with normal peripheral blood lymphocytes. Expression levels were normalized to actin and the log 2 expression levels were determined from the ratio of the sample value to the normal tissue value (cDNA synthesis and PCR amplification were repeated three to four times).
PVT1-Associated miRNAs and the MYC/PVT1 Genomic Locus
The location of the validated miRNAs was positioned with respect to the human and mouse PVT1 loci and to known breakpoints associated with human BLs, mouse PCTs, and retroviral integration site (Fig. 1B) . Although there are significant differences in the positions of the annotated exons of the human and mouse PVT1 transcripts, the relative positions of the miRNAs are highly conserved between species. Interestingly, one of the identified miRNA sequences, hsa-miR-1204, is located 60 kb downstream of MYC and very close to a small CpG island. The mouse counterpart, mmu-miR-1204, is located in the same region and close to a large cluster (>40) of retroviral integration site identified by GENETRAP technology 8 and close to a small cluster of T(15;16) breakpoints in vPCTs (39) . Furthermore, a sequence-based BLAST search confirmed that the hsa-miR-1204 sequence overlaps precisely with the PVT1 exon 1b. As mentioned previously, this exon is found frequently as part of the PVT1/IG fusion transcripts generated by vBL breakpoints (Fig. 1B; Supplementary Fig.  S1A ), and a reverse transcription-PCR assay using primers from the PVT1 exon 1b and IG constant regions usually identifies vBL and vPCT breakpoints (15, 16) . The location of hsa-miR-1204 within exon 1b of PVT1 is of particular interest, as the predicted hsa-miR-1204 precursor sequence extends beyond the consensus splice site of the PVT1 exon 1b. Thus, it is unlikely that hsa-miR-1204 is merely captured as part of the PVT1/IG fusion transcript observed in vBLs. No other miRNAs were associated with annotated PVT1 exons, although both mouse miR-1206 and miR-1205 are found close to the largest cluster of vPCT breakpoints and exon 1 of the mouse PVT1 cDNA.
Analysis of the hsa-miR-1204 Putative Precursor Sequences
All but one of the identified PVT1-associated miRNAs seem to be transcribed in the same orientation indicating shared regulatory elements. To begin to dissect the transcriptional properties of PVT1-associated miRNA transcripts, we initially focused our efforts on the precursor transcript associated with hsa-miR-1204, as its location at the amino-terminal region of PVT1 transcription suggests that suitable promoters and transcription initiation signals are likely to be nearby. Initially, we used primer extension from both sense-and antisense-based primers corresponding to hsa-miR-1204 to confirm the presence of a precursor miRNA transcript. Transcripts of f75 nt corresponding to hsa-miR-1204 were found to be abundant in the antisense direction, whereas virtually no transcripts were found using a sense oligonucleotide (data not shown). Next, we used 5 ¶ rapid amplification of cDNA ends (RACE) analysis to define the start of hsa-miR-1204. For comparison, we also synthesized RACE products that would define the transcriptional start sites for hsa-miR-1206 Expression levels were normalized to actin and the log 2 expression levels were determined from the ratio of the sample value to the normal tissue value. Expression levels were normalized to actin and the log 2 expression levels were determined from the ratio of the sample value to the normal tissue value (cDNA synthesis and PCR amplification were repeated three to six times). and hsa-miR-155 (Fig. 2) . Sequence analysis of the RACE products identified f150 to 175 nt of sequence in the 5 ¶ flanking region of each mature miRNA. In each case, a reasonable consensus transcriptional start sequence (YYA +1 NT/ AYY) is found close to the beginning of the RACE product (40) . A sequence variation (A/G) that lies at the beginning of the complementary strand in hsa-miR-1206 was identified by direct sequencing of PCR products from the peripheral blood lymphocytes of several healthy individuals (Fig. 2) . A sequence variant has also been annotated that falls at the 3 ¶ end of the hsa-miR-1208 precursor (dbSNP:rs2648841). Although functional studies will be necessary to firmly establish whether these sequence variants influence the efficiency of miR processing, it is noteworthy that sequence variations in the 3 ¶ region of hsamiR-16-1 and hsa-miR-15a have been thought to affect expression in chronic lymphocytic leukemia patients (41) . The putative precursor structure for each of these miRNAs was also examined in the mouse, and their conservation of sequence and size strengthened the assignment of precursors to these structures ( Supplementary Fig. S3 ).
Expression Analyses of PVT1-Associated miRNAs in Normal and Tumor Cells by Quantitative RT-PCR
There is increasing evidence that many miRNAs play an important role in development and/or differentiation and that their deregulated expression may be a contributing factor in a variety of cancers. Given the association of the PVT1 region with BLs and PCTs, we first examined the expression of mmu-miR-1204 and mmu-miR-1206 precursors in a series of murine cell lines representing different stages of B-cell differentiation ( Fig. 3A; ref. 42) . To perform this analysis, we designed and implemented real-time RT-PCR assays using the sequences obtained from the RACE experiments with primers that would recognize the precursor miRNA transcripts in either human or mouse, accordingly. The rationale behind targeting precursors in the real-time assay was to increase the specificity and eliminate size bias in the targeted RNAs. From this analysis, it is apparent that expression of both mmu-miR-1204 and mmumiR-1206 transcripts seems to be higher in mature as opposed to immature stages of B cells. The highest levels, in fact, are found in cell lines expressing IG E (NFS3, M315 and M104E). In one vPCT cell line (ABPC4), high levels of mmu-miR-1204 are found but low levels of mmu-miR-1206 are observed. In contrast, another vPCT cell line (ABPC20) shows high levels of mmu-miR-1206 and low levels of mmu-miR-1204. Although limited samples were examined, this analysis showed no direct correlation between miR-PVT1 -based miRNA expression and MYC transcription (MYC protein was not assayed). We also quantified the expression of the miRNA precursors corresponding to hsa-miR-1204 and hsa-miR-1206 in a limited set of human B-cell tumor samples representing conventional T(8;14) (Namalwa or CA46) and vBL T(8:22; PA682) samples (Fig. 3B) . In concert with the findings in the mouse B-cell lines, hsa-miR-1204 seems to be expressed abundantly in CA46, which produces both IG E and n. In contrast, Namalwa, which is also a dual IG E/n producer, does not show high levels of hsamiR-1204 by quantitative RT-PCR, although hsa-miR-1206 levels are high (it should be noted that the Northern blot analysis in Fig. 1A seems to show higher levels of hsa-miR-1204 in Namalwa due to increased RNA loading).
In addition to genomic rearrangements affecting the PVT1 region, a large number of different types of tumors, both hematopoietic and epithelial, show genomic coamplification of the MYC/PVT1 region (Supplementary Fig. S1B; refs. 18-26) . For example, a recent study of head and neck squamous cell carcinoma found evidence of amplification of MYC (38%) or PVT1 (20%) or both (14%), and concluded that amplification of the PVT1 region must activate MYC as a result of cis-acting interaction (22) . A similar finding of MYC and PVT1 coamplification (two to five copies) in 8% of primary breast tumors (n = 311) showed a significant correlation with rapidly growing and progressive cancer (18) . In some breast cell lines (i.e., SKBR3, MDA-MB-231, and MCF-7), detailed comparative genomic hybridization studies have revealed small nonamplified regions (and/or microdeletions) within the MYC/ PVT1 amplicon, suggesting that certain regions may not be coamplified (Supplementary Fig. S1B; ref. 19) . 9 Therefore, we examined the copy number of hsa-miR-1204 compared with MYC (Fig. 4) . Application of real-time PCR to genomic DNA purified from two breast cancer cell lines (SKBR3, MDA-MB-231) compared with DNA from normal healthy individuals was conducted using primers corresponding to MYC, hsa-miR-1204, and TP53 (as a control). DNA from both SKBR3 and MDA-MB-231 cells displayed a 1.5-to 2-fold amplification of copy number of MYC and a 2.0-to 2.5-fold increase in copy number for hsa-miR-1204. We also tested MYC/PVT1 -amplified cell lines compared with normal breast and colon RNA using a quantitative RT-PCR precursor assay for hsamiR-1204 and MYC transcription (Fig. 4) . Enhanced expression of both MYC and hsa-miR-1204 was seen in two colon cell lines (HCT-116, COLO-320) as well as in both of the breast cancer cell lines.
Transduction of Mouse Pre -B-Cell Lines with miR-1204 Results in Overexpression of MYC
We further investigated a possible link between MYC and miR-1204 expression by transducing mouse pro-B and mouse pre-B cells with lentiviral-based vectors expressing either human or mouse miR-1204 precursors (Fig. 5) . Although stably transduced cells showed appropriate expression of the miR-1204 precursor (Fig. 5B and C) , Myc expression was enhanced by the overexpression of either the human or mouse miR-1204 precursor, but only in the pre -B cell (Fig. 5A ). This effect on Myc expression is most likely to be indirect as there are no obvious direct binding sites for miR-1204 within the 3 ¶ untranslated region of Myc where one might expect miRNA binding (data not shown).
Discussion
The study of unstable genomic regions has been widely used to identify loci contributing to disease processes, particularly cancer. Genetic rearrangements of human chromosome 8q24 and the syntenic region in mouse (chromosome 15) are associated with lymphoma, and amplification of this same region has also been observed in a variety of epithelial cancers (18) (19) (20) (21) (22) (23) (24) (25) (26) . The deregulated expression of MYC, located within this region, is obviously a key factor in the development of many tumors, but MYC does not act alone (reviewed in ref. 43) . Thus, many studies have focused on delineating the role of the physically linked PVT1 locus. Recently, PVT1 has been found to be one of the most significantly up-regulated transcripts in EA-hsa-miR-155 transgenic mice that readily develop B-cell leukemia/lymphoma (44) . The PVT1 transcript was also found among a small subset of genes that were overexpressed following RNA interference -mediated down-regulation and/ or Gleevec inhibition of BCR/ABL in chronic myelogenous leukemia (K562) cells (45) . In earlier studies, a knockout of the Pvt1 locus in the mouse was embryonically lethal, 10 suggesting that PVT1 may play a critical role in normal development. However, the sequence and structural differences in the location of exons between mouse and human PVT1 transcripts, as well as the vast level of alternative splicing associated with these transcripts, has complicated the interpretation of these results. Furthermore, lack of a protein product for PVT1 has severely limited the extent of studies, despite its apparent involvement in translocations and amplification in so many different forms of cancer. To begin to answer these questions, we formulated the hypothesis that noncoding miRNAs might be present within the PVT1 locus and have now validated the presence of seven new 9 P. Meltzer, personal communication. 10 K. Huppi, unpublished data. mature miRNA sequences derived from this region. With the exception of hsa-miR-2PVT1 (which is expressed at much lower levels than the other miRNAs identified in this study), all of the miRNAs identified are transcribed in the same direction as both MYC and PVT1.
A number of studies have shown that the normal expression of miRNAs can be affected by chromosomal translocation, amplification, or deletion and that this deregulated expression has the potential to have a direct consequence on the function of these miRNAs (3, 4) . Recently, the oncogenic potential of deregulated miRNA expression has also been revealed through the use of a retroviral mutagenesis approach, which shows that retroviral integration of a murine leukemia virus into the mir-17-92 cluster on mouse chromosome 14 increased expression of the primary miRNA transcript and induced development of T-cell lymphomas (46) . The miRNAs identified in this study may also be susceptible to some of the transcriptional alterations previously described for MYC and PVT1 as a result of the chromosomal translocations, amplifications, or retroviral integrations commonly associated with the chromosome 8q24 region (and the syntenic region in mouse). To address the possible effects of previously defined genomic and transcriptional alterations within this region on the miRNAs identified in this study, we focused initially on the expression of miR-1204 as this miRNA maps closest to MYC in human and mouse, partially overlaps with a previously defined exon of human PVT1 and resides close to a cluster of retroviral integration site in mouse. We observed high levels of the mmumiR-1204 precursor in all vBL and vPCT samples. Interestingly, we have observed that the highest levels of miR-1204 transcription are found in many samples that abundantly express IG E as their light chain (NFS3, M315, M104E, and CA46). If this correlation can be confirmed in additional samples, this may suggest a role miR-1204 in controlling expression of IG E or IG light chain genes in general. We also asked whether genomic and transcriptional changes associated with this region seen in solid tumors could be extended to the PVT1-based miRNAs. An increase in copy number and expression for hsa-miR-1204, consistent with that seen for MYC, was also observed in several breast and colon cell lines. To further substantiate a connection between the PVT1 based miRNAs and MYC, we constitutively overexpressed miR-1204 (mouse and human) in mouse pro -B-cell or pre -B-cell lines. Increased Myc transcription was observed in the pre -B-cell line only, suggesting that a stage-specific down-regulation of a target(s) must have some indirect effect on Myc expression. Although further studies will be required to determine the possible function of the miRNAs identified in this study and their role in tumorigenesis, the current study illustrates the value of looking for the presence of regulatory RNAs in chromosomal regions associated with cancer where no proteinencoding gene candidate has formally been identified.
Materials and Methods
Cell Lines
The BL cell lines Raji, Namalwa, PA682, and CA46 were maintained in RPMI 1640 plus 10% fetal bovine serum and are the generous gifts of Drs. G. Tosato, W. Shi, M. Zajac-Kaye, and K. Bhatia [National Cancer Institute (NCI), Bethesda, MD]. The breast cancer cell lines MDA-MB-231, MCF7, SK-BR3, and the colon cancer cell line HCT-116, 11 were maintained in DMEM plus 5% fetal bovine serum. Mouse PCTs and cell lines representing various stages of B-cell development have been described previously (42) . Mouse pro-B (BAF3) and pre-B (v-abl-PreB1) cell lines were maintained in RPMI 1640 supplemented with interleukin-3 (10%) for the BAF-3 cells and 2-hME (5mmol/L) for v-abl-PreB1.
Molecular Analysis of miRNAs
Northern analysis was conducted using small RNA (less than %30 nt) extracted from total RNA according to the manufacturer's recommendation (Ambion, Inc.) and standard gel electrophoresis, Northern blot transfer, and hybridization to 32 P-labeled riboprobes. For additional details, see Supplementary Methods. The methods used for cloning PVT1 exons, primer extension, and 5 ¶ RACE studies of precursor miRNA sequences and quantitative PCR analysis of miRNA copy number and expression are detailed in Supplementary Methods. The generation of lentiviral-based plasmids expressing hsa-miR-1204 and mmu-miR-1204, viral production, and the selection of stably transduced cell populations is described in Supplementary Methods. The sequences of the oligonucleotide primers used in this study are shown in Supplementary  Table S1 .
